uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2024-31-2-10-18uzspbgmu-1068Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESТиазолопиримидиниевые системы с кватернизованным атомом азота как перспективные противоопухолевые агентыThiazolopyrimidinium systems with a quaternized nitrogen atom as promising anticancer agentshttps://orcid.org/0000-0002-5640-4077ПапоновБ. В.PaponovB. V.

Папонов Борис Владимирович - ассистент кафедры общей и биоорганической химии.

Санкт-Петербург

Paponov Boris V. - Associate Professor of the Department of General and Bioorganic Chemistry.

Saint Petersburg

paponov.orgchem@gmail.comhttps://orcid.org/0000-0003-3060-2232ШемчукО. С.ShemchukO. S.

Шемчук Ольга Сергеевна - аспирант, специалист по учебно-методической работе кафедры общей и биоорганической химии, Первый Санкт-Петербургский ГМУ им. акад. И. П. Павлова, младший научный сотрудник отдела фундаментальных исследований, РНЦРХТ имени академика А.М. Гранова

Санкт-Петербург

Shemchuk Olga S. - Postgraduate Student, Specialist in Educational and Methodological Work of the Department of General and Bioorganic Chemistry, Pavlov University (Saint Petersburg, Russia), Junior Research Fellow of the Department of Fundamental Researches, A. M. Granov RRCRST.

Saint Petersburg

olja.shemchuk17@gmail.comhttps://orcid.org/0000-0001-8174-7461МайстренкоД. Н.MaistrenkoD. N.

Майстренко Дмитрий Николаевич - доктор медицинских наук, Директор.

Санкт-Петербург

Maistrenko Dmitrii N. - Dr. of Sci. (Med.), Director, A. M. Granov RRCRST.

Saint Petersburg

may68@mail.ruhttps://orcid.org/0000-0003-3330-6324МолчановО. Е.MolchanovO. E.

Молчанов Олег Евгеньевич - доктор медицинских наук, руководитель отдела фундаментальных исследований.

197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 70

Molchanov Oleg E. - Dr. of Sci. (Med.), Head of the Department of Fundamental Researches, A. M. Granov RRCRST.

Saint Petersburg

molchanovo@mail.ruhttps://orcid.org/0000-0002-3717-0471ШаройкоВ. В.SharoykoV. V.

Шаройко Владимир Владимирович - доктор биологических наук, профессор кафедры общей и биоорганической химии, Первый Санкт-Петербургский ГМУ имени академика И. П. Павлова, ведущий научный сотрудник кафедры химии твердого тела Института химии, Санкт-Петербургский ГМУ, ведущий научный сотрудник отдела фундаментальных исследований РНЦРХТ имени академика А. М. Гранова.

197022, СанктПетербург, ул. Льва Толстого, д. 6-8

Vladimir V. Sharoyko - Dr. of Sci. (Biol.), Professor of the Department of General and Bioorganic Chemistry, Pavlov U, Leading Research Fellow of the Department of Solid State Chemistry of the Institute of Chemistry, St Petersburg U, Leading Research Fellow of the Department of Fundamental Researches, A. M. Granov RRCRST.

6-8, L’va Tolstogo str., Saint Petersburg, 197022

sharoyko@gmail.comhttps://orcid.org/0000-0003-2239-2044СеменовК. Н.SemenovK. N.

Семёнов Константин Николаевич - доктор химических наук, профессор кафедры общей и биоорганической химии, Первый Санкт-Петербургский ГМУ им. акад. И. П. Павлова, главный научный сотрудник отдела фундаментальных исследований, РНЦРХТ имени академика А. М. Гранова, профессор кафедры химии твердого тела Института химии, Санкт-Петербургский ГУ.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8; 197758,  Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 70; 199034, Санкт-Петербург, Университетская наб., д. 7–9

Semenov Konstantin N. - Dr. of Sci. (Med.), Professor of the Department of General and Bioorganic Chemistry, Pavlov U, Chief Research Fellow of the Department of Fundamental Researches, A. M. Granov RRCRST, Professor of the Department of Solid State Chemistry of the Institute of Chemistry, St Petersburg U.

Saint Petersburg

semenov1986@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Министерства здравоохранения Российской ФедерацииРоссияPavlov UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Министерства здравоохранения Российской ФедерацииРоссияPavlov University; A.M. Granov Russian Research Centre for Radiology and Surgical TechnologiesRussian FederationФедеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Министерства здравоохранения Российской ФедерацииРоссияA.M. Granov Russian Research Centre for Radiology and Surgical TechnologiesRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»РоссияPavlov University; A.M. Granov Russian Research Centre for Radiology and Surgical Technologies; St Petersburg UniversityRussian Federation2024031120243121018Copyright © Папонов Б.В., Шемчук О.С., Майстренко Д.Н., Молчанов О.Е., Шаройко В.В., Семенов К.Н., 20242024Папонов Б.В., Шемчук О.С., Майстренко Д.Н., Молчанов О.Е., Шаройко В.В., Семенов К.Н.Paponov B.V., Shemchuk O.S., Maistrenko D.N., Molchanov O.E., Sharoyko V.V., Semenov K.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/1068

Тиазолопиримидиниевые системы с кватернизованным атомом азота привлекают все большее внимание в области разработки новых противоопухолевых препаратов. Их уникальная химическая структура и потенциальные биологические свойства делают их перспективными кандидатами для создания эффективных лекарственных средств. В последние годы исследования показали, что эти соединения обладают значительной активностью против различных типов опухолей, что обусловлено их способностью взаимодействовать с клеточными мишенями, нарушая процессы, критические для выживания и пролиферации опухолевых клеток. Настоящий обзор посвящен анализу текущего состояния исследований в области тиазолопиримидинов, включая синтез, механизмы действия и оценку их противоопухолевого потенциала, с акцентом на важность кватернизованного атома азота в их биологической активности.

Thiazolopyrimidinium systems with a quaternized nitrogen atom are attracting increasing attention in the development of new anticancer drugs. Their unique chemical structure and potential biological properties make them promising candidates for the development of effective drugs. In recent years, researches have shown that these compounds have significant activity against various types of tumors due to their ability to interact with cellular targets, disrupting processes critical for the survival and proliferation of tumor cells. This review examines the current state of researches on thiazolopyrimidines, including synthesis, mechanisms of action, and evaluation of their antitumor potential, with an emphasis on the importance of the quaternized nitrogen atom in their biological activity.

хинолинкватернизованный атомтопоизомеразацитостатикилипосомыquinolinequaternized atomtopoisomerasecytostaticsliposomesРабота выполнена при финансовой поддержке Министерства Здравоохранения Российской Федерации (государственное задание по теме «Создание препарата на основе наноформ инновационных синтетических противоопухолевых антибиотиков, включающих гетероциклические системы с кватернизованным атомом азота и стирильными фрагментами в виде конъюгатов с векторами адресной доставки к микроокружению опухоли»)The work was carried out with the financial support of the Ministry of Health of the Russian Federation (state assignment on the topic «Creation of a drug based on nanoforms of innovative synthetic antitumor antibiotics, including heterocyclic systems with a quaternized nitrogen atom and styryl fragments in the form of conjugates with targeted delivery vectors to the tumor microenvironment»)ReferencesMiller K. D., Siegel R. L., Lin C. C. et al. Cancer treatment and survivorship statistics, 2016 // CA Cancer J Clin. – 2016. – Vol. 66, № 4. – P. 271–289.Miller K. D., Siegel R. L., Lin C. C. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.Zhong L., Li Y., Xiong L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives //Signal Transduct Target Ther. – 2021. – Vol. 6, № 1. – P. 201.Zhong L., Li Y., Xiong L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond // Nat Rev Cancer. – 2006. – Vol. 6, № 10. – P. 789–802.Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.Dezhenkova L. G., Tsvetkov V. B., Shtil A. A. Topoisomerase I and II inhibitors: chemical structure, mechanisms of action and role in cancer chemotherapy // Russian Chemical Reviews. – 2014. – Vol. 83, № 1. – P. 82–94.Dezhenkova L. G., Tsvetkov V. B., Shtil A. A. Topoisomerase I and II inhibitors: chemical structure, mechanisms of action and role in cancer chemotherapy. Russian Chemical Reviews. 2014;83(1):82–94.Berman H. M., Young P. R. The interaction of intercalating drugs with nucleic acids // Annu Rev Biophys Bioeng. – 1981. – Vol. 10, № 1. – P. 87–114.Berman H. M., Young P. R. The interaction of intercalating drugs with nucleic acids. Annu Rev Biophys Bioeng. 1981;10(1):87–114.Ashley J. N., Browning C. H., Cohen J. B., Gulbransen R. The antiseptic and trypanocidal properties of some anil and styryl derivatives of 4 amino quinaldine // Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. – The Royal Society London, 1933. – Vol. 113, № 783. – P. 293–299.Ashley J. N., Browning C. H., Cohen J. B., Gulbransen R. The antiseptic and trypanocidal properties of some anil and styryl derivatives of 4 amino quinaldine. Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. The Royal Society London. 1933;113(783):293–299.Glen W. L., Sutherland M. M. J., Wilson F. J. et al. The preparation and therapeutic properties of certain 4-substituted quinoline derivatives // Journal of the Chemical Society (Resumed). – Royal Society of Chemistry, 1939. – P. 489–492.Glen W. L., Sutherland M. M. J., Wilson F. J. et al. The preparation and therapeutic properties of certain 4-substituted quinoline derivatives. Journal of the Chemical Society (Resumed). Royal Society of Chemistry. 1939:489–492.Browning C. H., Cohen J. B., Ellingworth S., Gulbransen R. The antiseptic properties of the amino derivatives of styryl and anil quinoline // Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. – The Royal Society London, 1926. – Vol. 100, № 703. – P. 293–325.Browning C. H., Cohen J. B., Ellingworth S., Gulbransen R. The antiseptic properties of the amino derivatives of styryl and anil quinoline. Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. The Royal Society London. 1926; 100(703):293–325.Hughes B., Bates A. L., Bahner C. T., Lewis M. R. Regression of transplanted rat lymphoma No. 8 following oral administration of either 4-(p-Dimethylaminostyryl) quinoline methiodide or methochloride // Proceedings of the Society for Experimental Biology and Medicine. – SAGE Publications Sage UK: London, England, 1955. – Vol. 88, № 2. – P. 230–232.Hughes B., Bates A. L., Bahner C. T., Lewis M. R. Regression of Transplanted Rat Lymphoma No. 8 Following Oral Administration of Either 4-(p-Dimethylaminostyryl) quinoline Methiodide or Methochloride. Proceedings of the Society for Experimental Biology and Medicine. SAGE Publications Sage UK: London, England, 1955; 88(2):230–232.Bahner C. T., Pace E. S., Prevost R. Quaternary salts of styryl pyridines and quinolines // J Am Chem Soc. – ACS Publications, 1951. – Vol. 73, № 7. – P. 3407–3408.Bahner C. T., Pace E. S., Prevost R. Quaternary salts of styryl pyridines and quinolines. J Am Chem Soc. ACS Publications. 1951;73(7):3407–3408.Gutsulyak B. M. Biological Activity of Quinolinium Salts // Russian Chemical Reviews. – 1972. – Vol. 41, № 2. – P. 187–202.Gutsulyak B. M. Biological Activity of Quinolinium Salts. Russian Chemical Reviews. 1972;41(2):187–202.Fortuna C. G., Barresi V., Bonaccorso C. et al. Design, synthesis and in vitro antitumour activity of new heteroaryl ethylenes // Eur J Med Chem. – 2012. – Vol. 47. – P. 221–227.Fortuna C. G., Barresi V., Bonaccorso C. et al. Design, synthesis and in vitro antitumour activity of new heteroaryl ethylenes. Eur J Med Chem. 2012;47:221–227.Barresi V., Bonaccorso C., Consiglio G. et al. Modeling, design and synthesis of new heteroaryl ethylenes active against the MCF-7 breast cancer cell-line // Mol Biosyst. – The Royal Society of Chemistry, 2013. – Vol. 9, № 10. – P. 2426–2429.Barresi V., Bonaccorso C., Consiglio G. et al. Modeling, design and synthesis of new heteroaryl ethylenes active against the MCF-7 breast cancer cell-line. Mol Biosyst. The Royal Society of Chemistry. 2013;9(10):2426–2429.Bongiorno D., Musso N., Bonacci P. G. et al. Heteroaryl-ethylenes as new lead compounds in the fight against high priority bacterial strains // Antibiotics. – MDPI, 2021. – Vol. 10, № 9. – P. 1034.Bongiorno D., Musso N., Bonacci P. G. et al. Heteroaryl-ethylenes as new lead compounds in the fight against high priority bacterial strains. Antibiotics. MDPI, 2021; 10(9):1034.Bivona D. A., Mirabile A., Bonomo C. et al. Heteroaryl­ethylenes as new effective agents for high priority gram­positive and gram­negative bacterial clinical isolates // Antibiotics. – 2022. – Vol. 11, № 6. – P. 767.Bivona D. A., Mirabile A., Bonomo C. et al. Heteroaryl­ethylenes as new effective agents for high priority gram­positive and gram­negative bacterial clinical isolates. Antibiotics. 2022;11(6):767.Xie X., Zuffo M., Teulade-Fichou M. P., Granzhan A. Identification of optimal fluorescent probes for G-quadruplex nucleic acids through systematic exploration of mono- And distyryl dye libraries // Beilstein Journal of Organic Chemistry. – Beilstein­Institut Zur Forderung der Chemischen Wissenschaften, 2019. – Vol. 15. – P. 1872–1889.Xie X., Zuffo M., Teulade-Fichou M. P., Granzhan A. Identification of optimal fluorescent probes for G-quadruplex nucleic acids through systematic exploration of monoAnd distyryl dye libraries. Beilstein Journal of Organic Chemistry. Beilstein­Institut Zur Forderung der Chemischen Wissenschaften. 2019;15:1872–1889.Long W., Zheng B. X., Huang X. H. et al. Molecular recognition and imaging of human telomeric G­Quadruplex DNA in live cells: a systematic advancement of thiazole orange scaffold to enhance binding specificity and inhibition of gene expression // J Med Chem. – J Med Chem, 2021. – Vol. 64, № 4. – P. 2125–2138.Long W., Zheng B. X., Huang X. H. et al. Molecular recognition and imaging of human telomeric G­Quadruplex DNA in live cells: a systematic advancement of thiazole orange scaffold to enhance binding specificity and inhibition of gene expression. J Med Chem. 2021;64(4):2125–2138.Sucunza D., Cuadro A. M., Alvarez-Builla J., Vaquero J. J. Recent advances in the synthesis of azonia aromatic heterocycles // J Org Chem. – 2016. – Vol. 81, № 21. – P. 10126–10135.Sucunza D., Cuadro A. M., Alvarez-Builla J., Vaquero J. J. Recent Advances in the Synthesis of Azonia Aromatic Heterocycles. J Org Chem. 2016;81(21):10126–10135.Krey A. K., Hahn F. E. Berberine: Complex with DNA //Science (1979). – 1969. – Vol. 166, № 3906. – P. 755–757.Krey A. K., Hahn F. E. Berberine: Complex with DNA. Science (1979). 1969;166(3906):755–757.Bhadra K., Maiti M., Kumar G. S. DNA-binding cytotoxic alkaloids: comparative study of the energetics of binding of berberine, palmatine, and coralyne // DNA Cell Biol. – 2008. – Vol. 27, № 12. – P. 675–685.Bhadra K., Maiti M., Kumar G. S. DNA-binding cytotoxic alkaloids: comparative study of the energetics of binding of berberine, palmatine, and coralyne. DNA Cell Biol. 2008; 27(12):675–685.Bazzicalupi C., Ferraroni M., Bilia A. R. et al. The crystal structure of human telomeric DNA complexed with berberine: an interesting case of stacked ligand to G­tetrad ratio higher than 1:1 // Nucleic Acids Res. – 2013. – Vol. 41, № 1. – P. 632–638.Bazzicalupi C., Ferraroni M., Bilia A. R. et al. The crystal structure of human telomeric DNA complexed with berberine: an interesting case of stacked ligand to G­tetrad ratio higher than 1:1. Nucleic Acids Res. 2013;41(1): 632–638.Molina A., Vaquero J. J., Garcia-Navio J. L. et al. Synthesis and DNA binding properties of γ-carbolinium derivatives and benzologues // J Org Chem. – 1996. – Vol. 61, № 16. – P. 5587–5599.Molina A., Vaquero J. J., Garcia-Navio J. L. et al. Synthesis and DNA Binding Properties of γ-Carbolinium Derivatives and Benzologues. J Org Chem. 1996;61(16):5587–5599.Molina A., Vaquero J. J., García-Navio J. L. et al. Azonia derivatives of the γ-carboline system. A new class of DNA intercalators // Bioorg Med Chem Lett. – Pergamon, 1996. – Vol. 6, № 13. – P. 1453–1456.Molina A., Vaquero J. J., García-Navio J. L. et al. Azonia derivatives of the γ-carboline system. A new class of DNA intercalators. Bioorg Med Chem Lett. Pergamon, 1996;6(13):1453–1456.Ihmels H., Faulhaber K., Vedaldi D. et al. Intercalation of organic dye molecules into double-stranded DNA. Part 2: the annelated quinolizinium ion as a structural motif in DNA intercalators // Photochem Photobiol. – Wiley, 2005. – Vol. 81, № 5. – P. 1107–1115.Ihmels H., Faulhaber K., Vedaldi D. et al. Intercalation of organic dye molecules into double-stranded DNA. Part 2: the annelated quinolizinium ion as a structural motif in DNA intercalators. Photochem Photobiol. Wiley. 2005; 81(5):1107–1115.Prasad P., Khan I., Sasmal P. K. et al. Planar triazinium cations from vanadyl-mediated ring cyclizations: the thiazole species for efficient nuclear staining and photocytotoxicity // Dalton Transactions. – The Royal Society of Chemistry, 2013. – Vol. 42, № 13. – P. 4436–4449.Prasad P., Khan I., Sasmal P. K. et al. Planar triazinium cations from vanadyl-mediated ring cyclizations: the thiazole species for efficient nuclear staining and photocytotoxicity. Dalton Transactions. The Royal Society of Chemistry. 2013; 42(13):4436–4449.Pithan P. M., Decker D., Druzhinin S. I. et al. 8-Styryl-substituted coralyne derivatives as DNA binding fluorescent probes // RSC Adv. – 2017. – Vol. 7, № 18. – P. 10660–10667.Pithan P. M., Decker D., Druzhinin S. I. et al. 8-Styryl-substituted coralyne derivatives as DNA binding fluorescent probes. RSC Adv. 2017;7(18):10660–10667.Sha X. L., Yang X. Z., Wei X. R. et al. A mitochondria/ lysosome-targeting fluorescence probe based on azonia-cyanine dye and its application in nitroreductase detection //Sens Actuators B Chem. – Elsevier, 2020. – Vol. 307. – P. 127653.Sha X. L., Yang X. Z., Wei X. R. et al. A mitochondria/ lysosome-targeting fluorescence probe based on azonia-cyanine dye and its application in nitroreductase detection. Sens Actuators B Chem. Elsevier. 2020;307:127653.Chen Y., Wei X. R., Sun R. et al. The application of azonia-cyanine dyes for nucleic acids imaging in mitochondria //Sens Actuators B Chem. – Elsevier, 2019. – Vol. 281. – P. 499–506.Chen Y., Wei X. R., Sun R. et al. The application of azonia-cyanine dyes for nucleic acids imaging in mitochondria. Sens Actuators B Chem. Elsevier. 2019;281: 499–506.Sha X. L., Niu J. Y., Sun R. et al. Synthesis and optical properties of cyanine dyes with an aromatic azonia skeleton // Organic Chemistry Frontiers. – The Royal Society of Chemistry, 2018. – Vol. 5, № 4. – P. 555–560.Sha X. L., Niu J. Y., Sun R. et al. Synthesis and optical properties of cyanine dyes with an aromatic azonia skeleton. Organic Chemistry Frontiers. The Royal Society of Chemistry. 2018;5(4):555–560.Suárez R. M., Bosch P., Sucunza D. et al. Targeting DNA with small molecules: a comparative study of a library of azonia aromatic chromophores // Org Biomol Chem. – 2015. – Vol. 13, № 2. – P. 527–538.Suárez R. M., Bosch P., Sucunza D. et al. Targeting DNA with small molecules: a comparative study of a library of azonia aromatic chromophores. Org Biomol Chem. 2015; 13(2):527–538.Bosch P., García V., Bilen B. S. et al. Imidazopyridinium cations: A new family of azonia aromatic heterocycles with applications as DNA intercalators // Dyes and Pigments. – 2017. – Vol. 138. – P. 135–146.Bosch P., García V., Bilen B. S. et al. Imidazopyridinium cations: A new family of azonia aromatic heterocycles with applications as DNA intercalators. Dyes and Pigments. 2017;138:135–146.Chuiguk V. A., Rudnik I. A. Mesoionic 1,2,4-triazolo[5′,1′:3,4]-1,2,4-triazolo[1,5-a]-pyrimidines // Chem Heterocycl Compd (N Y). – 1982. – Vol. 18, № 7. – P. 762–762.Chuiguk V. A., Rudnik I. A. Mesoionic 1,2,4-triazolo[5?,1??3,4]-1,2,4-triazolo[1,5-a]-pyrimidines. Chem Heterocycl Compd (N Y). 1982;18(7):762–762.De Jong W. H., Borm P. J. Drug delivery and nanoparticles: Applications and hazards // Int J Nanomedicine. – 2008. – Vol. 3, № 2. – P. 133.De Jong W. H., Borm P. J. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 2008; 3(2):133.Aslan B., Ozpolat B., Sood A. K., Lopez-Berestein G. Nanotechnology in cancer therapy // J Drug Target. – 2013. – Vol. 21, № 10. – P. 904–913.Aslan B., Ozpolat B., Sood A. K., Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target. 2013; 21(10):904–913.Roger E., Lagarce F., Garcion E., Benoit J.-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery // Nanomedicine. – 2010. – Vol. 5, № 2. – P. 287–306.Roger E., Lagarce F., Garcion E., Benoit J.-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine. 2010;5(2):287–306.Duncan R. Polymer conjugates as anticancer nanomed­ icines // Nat Rev Cancer. – 2006. – Vol. 6, № 9. – P. 688–701.Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9):688–701.Vega-Villa K. R., Takemoto J. K., Yáñez J. A. et al. Clinical toxicities of nanocarrier systems // Adv Drug Deliv Rev. – 2008. – Vol. 60, № 8. – P. 929–938.Vega-Villa K. R., Takemoto J. K., Yáñez J. A. et al. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev. 2008;60(8):929–938.Rihova B., Kubackova K. Clinical Implications of N­(2­Hydroxypropyl)Methacrylamide Copolymers // Curr Pharm Biotechnol. – 2003. – Vol. 4, № 5. – P. 311–322.Rihova B., Kubackova K. Clinical Implications of N­(2­Hydroxypropyl)Methacrylamide Copolymers. Curr Pharm Biotechnol. 2003;4(5):311–322.O’Brien M. E. R., Wigler N., Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl(CAELYXTM/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer // Annals of Oncology. – 2004. – Vol. 15, № 3. – P. 440–449.O’Brien M. E. R., Wigler N., Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYXTM/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Annals of Oncology. 2004;15(3):440–449.Pillai G. Nanomedicines for Cancer Therapy: An Update of FDA approved and those under various stages of development //SOJ Pharm Pharm Sci. – 2014. – Vol. 1, № 2.Pillai G. Nanomedicines for Cancer Therapy: An Update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci. 2014;1(2).Stinchcombe T. E. Nanoparticle albumin­bound paclitaxel: a novel cremphor­EL ® ­Free formulation of paclitaxel // Nanomedicine. – 2007. – Vol. 2, № 4. – P. 415–423.Stinchcombe T. E. Nanoparticle albumin-bound paclitaxel: a novel cremphor­EL ® ­Free formulation of paclitaxel. Nanomedicine. 2007;2(4):415–423.Xu R., Fisher M., Juliano R. L. Targeted albumin­based nanoparticles for delivery of amphipathic drugs // Bioconjug Chem. – 2011. – Vol. 22, № 5. – P. 870–878.Xu R., Fisher M., Juliano R. L. Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjug Chem. 2011;22(5):870–878.Ma N., Liu J., He W. et al. Folic acid­grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy // J Colloid Interface Sci. – Academic Press Inc., 2017. – Vol. 490. – P. 598–607.Ma N., Liu J., He W. et al. Folic acid-grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy. J Colloid Interface Sci. Academic Press Inc. 2017;490:598–607.Wang Y., Wu C. Site-specific conjugation of polymers to proteins // Biomacromolecules. – 2018. – Vol. 19, № 6. – P. 1804–1825.Wang Y., Wu C. Site-specific conjugation of polymers to proteins. Biomacromolecules. 2018;19(6):1804–1825.Eisele K., Gropeanu R., Musante A. et al. Tailored Albumin­based copolymers for receptor­mediated delivery of perylenediimide guest molecules // Macromol Rapid Commun. – 2010. – Vol. 31, № 17. – P. 1501–1508.Eisele K., Gropeanu R., Musante A. et al. Tailored Albumin­based copolymers for receptor­mediated delivery of perylenediimide guest molecules. Macromol Rapid Commun. 2010;31(17):1501–1508.Kopeckova K., Eckschlager T., Sirc J. et al. Nanodrugs used in cancer therapy // Biomedical Papers. – 2019. – Vol. 163, № 2. – P. 122–131.Kopeckova K., Eckschlager T., Sirc J. et al. Nanodrugs used in cancer therapy. Biomedical Papers. 2019;163(2): 122–131.

The authors declare that there are no conflicts of interest present.